about
Targeting angiogenesis in gynecologic cancersTyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatmentSunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectivesChronic VEGF blockade worsens glomerular injury in the remnant kidney modelRole of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies.Met-related receptor tyrosine kinase Ron in tumor growth and metastasis.Simultaneous determination of sunitinib and its two metabolites in plasma of Chinese patients with metastatic renal cell carcinoma by liquid chromatography-tandem mass spectrometry.Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.Recent advances in anti-angiogenic therapy of cancerSunitinib malate for the treatment of pancreas malignancies--where does it fit?Acute renal failure after treatment with sunitinib in a patient with multiple myeloma.Concomitant renal cell carcinoma and chronic myelogenous leukemia: use of a targeted approach.Synthesis of sericin-based conjugates by click chemistry: enhancement of sunitinib bioavailability and cell membrane permeation.The Importance of Descriptor-Based Clusterization in QSAR Models Development: Tyrosine Kinases Inhibitors as a Key Study.Quantitation of sunitinib, an oral multitarget tyrosine kinase inhibitor, and its metabolite in urine samples by nonaqueous capillary electrophoresis time of flight mass spectrometry.Discovery of 1,3-Diaryl-pyridones as Potent VEGFR-2 Inhibitors: Design, Synthesis, and Biological Evaluation.
P2860
Q26824766-04E7500F-67BD-4CBF-BE60-AF6D59BE47C1Q26998914-CB09C61E-B5DD-4900-86E8-79B5F0B2C03BQ28069560-477340B2-9DBF-458A-BB39-6E26CFB2EBBDQ28728129-4C7EAE9B-DC46-49A8-9B28-C082EE56EF6EQ33771212-ADE76D92-EFED-4F74-B517-4EFB1EE8F538Q33916081-68A16EBC-30EE-40FD-830F-60278D7F1E7BQ34460026-7D5B6668-651E-4FAF-9026-F8250AD87285Q35205410-A0656C22-F689-4399-8970-B6A28E6F3AE9Q37852512-77235696-FD07-453A-9F2E-3A429BB5AC7FQ38086310-225E8F81-8CBA-4869-BAFC-25BC425540F4Q40322647-67A405B2-C09F-4B27-B2F8-E1FDAFEED8DAQ43145503-6022AAAC-C077-4337-875F-69F9F742352EQ51144290-140197FC-A0D8-4164-B230-D47EB201F2DEQ51544030-37D85169-BD2D-4F60-99B4-82B0D5EE26F8Q53542598-E5E9E45A-52F5-4BFF-A2B2-5B5C1A1D81C6Q54228215-C666DAF6-1B3A-4C77-BB19-6CE93E78CE13
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Sunitinib malate.
@en
type
label
Sunitinib malate.
@en
prefLabel
Sunitinib malate.
@en
P2093
P1476
Sunitinib malate.
@en
P2093
Gilbert Deray
Hassane Izzedine
Irina Buhaescu
P2888
P304
P356
10.1007/S00280-006-0376-5
P50
P577
2006-11-30T00:00:00Z
P6179
1001792246